Testing Status of Transgenic model evaluation (Cyclophosphamide monohydrate) M970045

 

CASRN: 6055-19-2

Formula: C7-H15-Cl2-N2-O2-P.H2-O

Synonyms/Common Names

  • (+-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-
  • Cyclophosphamide monohydrate (Transgenic model evaluation)

Known Uses

Used in treatment of Hodgkins disease and lymphosarcomas

Chemical Properties

Toxicity Effects (HSDB)

Short-Term Toxicity

  • 2 weeks (Topical Application)  (C97011A)  Completed 
    • Mice: Tg.AC (FVB/N) Homozygous
    • Dose: MICE ONLY: 0, 12.5, 25, 50, 100, OR 200 MG/KG; 5/SEX DOSE; 2X/WEEK.
  • 2 weeks (Gavage)  (C97011B)  Completed 
    • Mice: Tg.AC (FVB/N) Homozygous
    • Dose: MICE ONLY: 0, 10, 20, 40, 60 OR 120 MG/KG; 5/SEX/DOSE; 2X/WEEK.
  • 26 weeks (Topical Application)  (C97011A)  Completed 
    • Mice: FVB/N; Mice: Tg.AC (FVB/N) Homozygous
    • Dose: TG.AC MICE: 0, 10, 30, OR 90 MG/KG; FVB/N MICE: 0, 90 MG/KG; 15/SEX/DOSE; 2X/WEEK.
  • 26 weeks (Gavage)  (C97011B)  Completed 
    • Mice: FVB/N; Mice: Tg.AC (FVB/N) Homozygous
    • Dose: TG.AC MICE: 0, 10, 30, 0R 60 MG/KG; FVB/N MICE: 0 OR 60 MG/KG; 15/SEX/DOSE; 2X/WEEK.

Genetic Toxicology

  • Micronucleus  (G10351)  Completed 
    • Rats: Wistar Han
    • Male Positive